Cell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic source

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 11, 2016, Pages 3006-3011

  Efimov, Grigory A ^a,b,j   Kruglov, Andrei A ^b,c,d   Khlopchatnikova, Zoya V ^a   Rozov, Fedor N ^b,d   Mokhonov, Vladislav V ^b   Rose John, Stefan ^e   Scheller, Jürgen ^f   Gordon, Siamon ^g   Stacey, Martin ^h   Drutskaya, Marina S ^a   Tillib, Sergei V ^d,i   Nedospasov, Sergei A ^a,b,c,d  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b LOBACHEVSKY STATE UNIVERSITY OF NIZHNY NOVGOROD   (Russian Federation)

^c A Leibniz Institute   (Germany)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

^e UNIVERSITY OF KIEL   (Germany)

^f Department of Orthopedic Surgery   (Germany)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF LEEDS   (United Kingdom)

ⁱ INSTITUTE OF GENE BIOLOGY   (Russian Federation)

^j NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

more..

Author keywords

Anti cytokine therapy; Autoimmunity; Bispecific antibody; Humanized mice; TNF

Indexed keywords

BISPECIFIC ANTIBODY; GALACTOSAMINE; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; COMPLEMENTARITY DETERMINING REGION; DIFFERENTIATION ANTIGEN; HYBRID PROTEIN; MEMBRANE ANTIGEN; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN; NEUTRALIZING ANTIBODY; SYNTHETIC DNA;

ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; BONE MARROW CELL; CONTROLLED STUDY; FLOW CYTOMETRY; LIVER TOXICITY; MONOCYTE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; CAMEL; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMISTRY; COMPLEMENTARITY DETERMINING REGION; GENETICS; HUMAN; IMMUNOLOGY; L CELL LINE; MUTATION; RANDOMIZATION; SECRETION (PROCESS);

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, DIFFERENTIATION; ANTIGENS, SURFACE; CAMELUS; CHEMICAL AND DRUG INDUCED LIVER INJURY; COMPLEMENTARITY DETERMINING REGIONS; GALACTOSAMINE; GENES, SYNTHETIC; HUMANS; L CELLS (CELL LINE); MACROPHAGES, PERITONEAL; MICE; MUTATION; RANDOM ALLOCATION; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84962602862     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1520175113     Document Type: Article

References (47)

1. Brennan FM, Maini RN, Feldmann M (1992) TNF alpha: A pivotal role in rheumatoid arthritis? Br J Rheumatol 31(5):293-298.
2. Braun J, et al. (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499-505.
3. Reinecker HC, et al. (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94(1):174-181.
4. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325(7): 467-472.
5. Mussi A, et al. (1997) Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 11(3):115-118.
6. Koski H, et al. (2001) Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjögren's syndrome. Clin Exp Rheumatol 19(2):131-137.
7. Reimund JM, et al. (1996) Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 16(3): 144-150.
8. Maini RN, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552-1563.
9. van Dullemen HM, et al. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109(1):129-135.
10. Braun J, et al. (2002) Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 359(9313):1187-1193.
11. Chaudhari U, et al. (2001) Efficacy and safety of infliximab monotherapy for plaquetype psoriasis: A randomised trial. Lancet 357(9271):1842-1847.
12. Mariette X, et al. (2004) Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 50(4):1270-1276.
13. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology 53(3):457-465.
14. Ramos-Casals M, et al. (2007) Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine (Baltimore) 86(4):242-251.
15. Anolik JH, et al. (2008) Cutting edge: Anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 180(2):688-692.
16. Mohan AK, Coté TR, Siegel JN, Braun MM (2003) Infectious complications of biologic treatments of rheumatoid arthritis. Curr Opin Rheumatol 15(3):179-184.
17. Pfeffer K (2003) Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 14(3-4):185-191.
18. Grivennikov SI, et al. (2005) Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: Protective and deleterious effects. Immunity 22(1):93-104.
19. Kruglov AA, Lampropoulou V, Fillatreau S, Nedospasov SA (2011) Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells. J Immunol 187(11):5660-5670.
20. Tumanov AV, et al. (2010) Cellular source and molecular form of TNF specify its distinct functions in organization of secondary lymphoid organs. Blood 116(18): 3456-3464.
21. Gooz M (2010) ADAM-17: The enzyme that does it all. Crit Rev Biochem Mol Biol 45(2):146-169.
22. Scheller J, Chalaris A, Garbers C, Rose-John S (2011) ADAM17: A molecular switch to control inflammation and tissue regeneration. Trends Immunol 32(8):380-387.
23. Kinne RW, Bräuer R, Stuhlmüller B, Palombo-Kinne E, Burmester GR (2000) Macrophages in rheumatoid arthritis. Arthritis Res 2(3):189-202.
24. Austyn JM, Gordon S (1981) F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 11(10):805-815.
25. Gordon S, Hamann J, Lin H-H, Stacey M (2011) F4/80 and the related adhesion-GPCRs. Eur J Immunol 41(9):2472-2476.
26. Kruglov A, et al. (2008) Mice in which human TNF is mediating both beneficial and deleterious functions: A model comparison of different blockade strategies. Cytokine 43(3):271.
27. Coppieters K, et al. (2006) Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 54(6):1856-1866.
28. Plagmann I, et al. (2009) Transglutaminase-catalyzed covalent multimerization of Camelidae anti-human TNF single domain antibodies improves neutralizing activity. J Biotechnol 142(2):170-178.
29. Conrad U, et al. (2011) ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock. Plant Biotechnol J 9(1):22-31.
30. Tillib SV, et al. (2014) Single-domain antibody-based ligands for immunoaffinity separation of recombinant human lactoferrin from the goat lactoferrin of transgenic goat milk. J Chromatogr B Analyt Technol Biomed Life Sci 949-950:48-57.
31. Olleros ML, et al. (2015) Control of mycobacterial infections in mice expressing human tumor necrosis factor (TNF) but not mouse TNF. Infect Immun 83(9):3612-3623.
32. Kruglov AA, et al. (2011) Modalities of experimental TNF blockade in vivo: Mouse models. Adv Exp Med Biol 691:421-431.
33. Keane J, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098-1104.
34. Williams EL, Gadola S, Edwards CJ (2009) Anti-TNF-induced lupus. Rheumatology (Oxford) 48(7):716-720.
35. Korkmaz U, et al. (2013) Adalimumab-induced psoriasis in a patient with Crohn's disease. Indian J Gastroenterol 32(2):135-136.
36. Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50(6):1740-1751.
37. Falvo JV, Tsytsykova AV, Goldfeld AE (2010) Transcriptional control of the TNF gene. Curr Dir Autoimmun 11:27-60.
38. Shebzukhov YV, et al. (2014) Dynamic changes in chromatin conformation at the TNF transcription start site in T helper lymphocyte subsets. Eur J Immunol 44(1): 251-264.
39. Ruuls SR, et al. (2001) Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15(4):533-543.
40. Alexopoulou L, et al. (2006) Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur J Immunol 36(10):2768-2780.
41. Allie N, et al. (2013) Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection. Sci Rep 3:1809.
42. Garcia I, et al. (2011) Roles of soluble and membrane TNF and related ligands in mycobacterial infections: Effects of selective and non-selective TNF inhibitors during infection. Adv Exp Med Biol 691:187-201.
43. Flynn JL, et al. (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2(6):561-572.
44. Eissner G, et al. (2000) Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 164(12):6193-6198.
45. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414(3):521-526.
46. Tillib SV, Ivanova TI, Vasilev LA (2010) Fingerprint-like analysis of "nanoantibody" selection by phage display using two helper phage variants. Acta Naturae 2(3):85-93.
47. Shingarova LN, et al. (1996) Human tumor necrosis factor mutants: Preparation and some properties. Bioorg Khim 22(4):243-251.